Artelo Biosciences has initiated a Phase 1 clinical trial of ART26.12, its lead FABP5 inhibitor, marking the first time...

NeuroSigma, Inc. announced the completion of enrollment for the ATTENS trial, a multicenter, double-blind, placebo-controlled study evaluating the effectiveness...

Rakovina Therapeutics has achieved a significant milestone by developing a shortlist of AI-generated molecules targeting ATR, designed for central...

ORIC Pharmaceuticals announced encouraging early safety and efficacy data from a Phase 1b trial of ORIC-944 combined with apalutamide...

Ashvattha Therapeutics secured up to $50 million in extended Series B funding, led by Tribe Capital with continued support...

NuView Life Sciences is transforming cancer diagnostics and treatment with its pioneering NV-VPAC1™ platform. This first-of-its-kind technology integrates in...

In an era where data is the cornerstone of innovation, the concept of dynamic consent is emerging as a...

At the 2024 Decentralized Trials & Research Alliance (DTRA) Annual Meeting, Dr. Amir Kalali of the DTRA and Dr....

Tenpoint Therapeutics announced positive topline results from its Phase 3 BRIO-II trial of BRIMOCHOL™ PF, a carbachol/brimonidine tartrate eye...

Rapport Therapeutics (Nasdaq: RAPP) announced positive Phase 1 results for RAP-219, a drug candidate for central nervous system disorders....